Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA approved expanded prescribing information for Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma.
Izervay (avacincaptad pegol intravitreal solution) is now approved without a limitation on duration of dosing, which provides greater flexibility for patients and physicians, the release said.
The label update follows the company’s supplemental new drug application resubmission in December 2024, based on